AN EXPERIMENTAL DRUG SHIELDED CELIAC PATIENTS DURING A GLUTEN CHALLENGE.
A 32-person study found less injury and fewer symptoms—but it is still early.
An early 32-person study found that three injections of experimental drug ANB033 reduced gluten-triggered intestinal damage and symptoms during a controlled challenge.
WHAT HAPPENED
Adults with celiac disease received three doses of ANB033 or placebo, then consumed a measured amount of gluten under study conditions. Researchers reported better preservation of intestinal tissue and fewer symptoms in the treated group. Six percent of treated participants needed additional medication compared with 47% of those receiving placebo.
The study is too small and early to establish safety, durability or real-world benefit. ANB033 remains experimental. People with celiac disease should not change a gluten-free diet on the basis of these results.
WHY THIS IS HOPESLOP
For celiac disease, the current treatment is vigilance: avoid gluten, every meal, every label, every day. An immune therapy that could eventually add protection would change the shape of that burden. Thirty-two participants are a beginning, not a finish line—but the mechanism cleared a meaningful early test.
ORIGINAL SOURCEReuters / AnaptysBioRead the original report
A DAILY ALLEGATION OF PROGRESS.
One good thing from the internet, every day. Nothing else.